Frontlight ResearchEarly access
WithdrawnPhase 1/2
CardiAQ-Edwards™ Transcatheter Mitral Valve Replacement (TMVR) Study
Key facts
- Who runs it
- Edwards Lifesciences
- Where
- Canada, Denmark, France, Germany, Italy, Netherlands, and Switzerland15 sites in 7 countriesChoose a country to see its sites
- Trial code
- Status
- Withdrawn
- Phase
- Phase 1/2
- Started
- Nov 2016
- Ended
- Oct 2024
- Type of study
- Interventional
- Treatments tested
- Transcatheter Mitral Valve Re-placement (TMVR) with the CardiAQ-Edwards™ Transcatheter Mitral Valve
- Record updated
- 9 January 2018
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- NYHA ≥ II
- Moderate/severe or severe mitral regurgitation
- Prohibitive risk for open-heart surgery
- Meets anatomical criteria
Who cannot take part
- Need for emergent or urgent surgery
- Prior mechanical aortic valve replacement
- Any prior surgical or transcatheter repair (excluding balloon valvuloplasty) or replacement of the mitral valve
- Clinically significant, untreated coronary artery disease
- Active infection
- Unsuitable anatomy
- Preexisting device in the left ventricular apex
- Limited life expectancy (< 12 months)
This trial has no sites in United States.
It has sites in 7 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
Clinical study to evaluate the safety and performance of the CardiAQ-Edwards™ Transcatheter Mitral Valve
The group in the trial
- TreatmentTreatment being tested
Treatment with the CardiAQ-Edwards™ Transcatheter Mitral Valve (transapical or transseptal delivery)
Treatment: Transcatheter Mitral Valve Re-placement (TMVR) with the CardiAQ-Edwards™ Transcatheter Mitral Valve
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- The RELIEF Trial: REduction or eLimination of mItral rEgurgitation in Degenerative or Functional Mitral Regurgitation With the CardiAQ-Edwards™ Transcatheter Mitral Valve
- Record updated
- 9 January 2018